Guardant Health Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(in thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| OPERATING ACTIVITIES: | |||
| Net loss | $(479,449) | $(654,588) | $(384,770) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation and amortization | 42,881 | 35,962 | 22,271 |
| Operating lease costs | 29,699 | 28,585 | 24,661 |
| Contingent consideration | 110 | 4,305 | 2,380 |
| Stock-based compensation | 90,759 | 94,685 | 151,449 |
| Amortization of debt issuance costs | 2,575 | 2,569 | 2,564 |
| Amortization of (discount) premium on marketable debt securities | (13,552) | 4,595 | 12,849 |
| Unrealized (gains) losses on marketable equity securities | (79,710) | 7,793 | — |
| Impairment of non-marketable equity securities and other related assets | 29,054 | 5,261 | — |
| Fair value adjustments of noncontrolling interest liability | — | 99,785 | — |
| Other | (1,182) | 21 | 47 |
| Cash effect of changes in operating assets and liabilities: | |||
| Accounts receivable, net | 8,378 | 375 | (44,353) |
| Inventory, net | (10,350) | (20,926) | (7,957) |
| Prepaid expenses and other current assets, net | (4,332) | 20,444 | (35,753) |
| Other assets, net | 1,298 | 11,698 | (4,182) |
| Accounts payable and accrued liabilities | 88,591 | 60,328 | 34,796 |
| Operating lease liabilities | (31,478) | (20,228) | 14,205 |
| Deferred revenue | 1,733 | 9,873 | 2,776 |
| Net cash used in operating activities | (324,975) | (309,463) | (209,017) |
| INVESTING ACTIVITIES: | |||
| Purchase of marketable debt securities | (629,902) | (303,757) | (900,808) |
| Maturity of marketable debt securities | 1,494,700 | 555,000 | 952,110 |
| Purchase of non-marketable equity securities and other related assets | (5,593) | (23,966) | (39,422) |
| Purchase of property and equipment | (20,486) | (77,461) | (75,035) |
| Other | 1,531 | — | — |
| Net cash provided by (used in) investing activities | 840,250 | 149,816 | (63,155) |
| FINANCING ACTIVITIES: | |||
| Proceeds from issuance of common stock under employee stock purchase plan | 10,154 | 9,316 | 9,753 |
| Proceeds from issuance of common stock upon exercise of stock options | 405 | 2,625 | 8,112 |
| Taxes paid related to net share settlement of restricted stock units | (11,197) | (7,878) | (83,759) |
| Proceeds from equity offerings | 493,116 | — | — |
| Payment of equity offering costs | (21,131) | — | — |
| Joint Venture Acquisition | — | (177,785) | — |
| Tender offer issued in connection with the Joint Venture Acquisition and acquisition related costs | — | (14,235) | — |
| Other | 6,028 | (1,136) | (930) |
| Net cash provided by (used in) financing activities | 477,375 | (189,093) | (66,824) |
| Net effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (911) | (1,600) | (1,693) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 991,739 | (350,340) | (340,689) |
| Cash, cash equivalents and restricted cash – Beginning of period | 141,948 | 492,288 | 832,977 |
| Cash, cash equivalents and restricted cash – End of period | $1,133,687 | $141,948 | $492,288 |
| Supplemental Disclosures of Cash Flow Information: | |||
| Cash paid for income taxes | $1,969 | $1,331 | $393 |
| Supplemental Disclosures of Noncash Investing and Financing Activities: | |||
| Operating lease liabilities arising from obtaining right-of-use assets | $5,015 | $4,073 | $171,382 |
| Purchase of property and equipment included in accounts payable and accrued liabilities | $5,279 | $8,291 | $8,892 |
| Reclassification of redeemable noncontrolling interest to noncontrolling interest liability | $— | $— | $78,000 |
| Reconciliation of cash, cash equivalents and restricted cash: | |||
| Cash and cash equivalents | $1,133,537 | $141,647 | $492,202 |
| Restricted cash – included in other assets, net | 150 | 301 | 86 |
| Total cash, cash equivalents and restricted cash | $1,133,687 | $141,948 | $492,288 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.